Pralatrexate for Peripheral T-Cell Lymphoma (PTCL): Chance Only Supports The Prepared Mind

医学 外周T细胞淋巴瘤 淋巴瘤 T细胞淋巴瘤 肿瘤科 甲氨蝶呤 药理学 癌症 内科学 T细胞 免疫学 免疫系统
作者
Serdar Altınay,Alev Kural,Aykut Özmen,Deniz Tural,Yusuf Sert
出处
期刊:Anti-cancer Agents in Medicinal Chemistry [Bentham Science]
卷期号:23 (3): 298-305 被引量:1
标识
DOI:10.2174/1871520622666220610151603
摘要

Due to their primary effects on DNA synthesis, antimetabolites are most effective against actively dividing cells and are significantly specific to the cell cycle phase. Pralatrexate (PDX), an antifolate metabolite designed to accumulate in cancer cells, was the first new agent approved by the US Food and Drug Administration for the treatment of resistant/recurrent peripheral T-cell lymphomas. PDX was a drug that is frequently used not only for PTCL, but also for cutaneous T-cell lymphoma (CTCL), extranodal natural killer (NK) / T-cell lymphoma.This article reviews Pralatrexate's history, pharmacokinetics, clinical phase studies including phases I, II and III, types of cancers it is effective on, drug side effects, inhibition mechanism and even its use in the treatment of other cancers with innovative methods, including its antiviral effect against SARS-CoV-2 infection.A comprehensive internet-based research was planned, covering all published and unpublished studies on the subject. We conducted this review in accordance with Preferred Reporting Items for systematic reviews and metaanalysis (PRISMA-P), and Cochrane Collaboration reporting items for systematic reviews and meta-analysis. The results of the studies in the articles were recorded to include all phase studies.Pralatrexate was structurally designed to have enhanced cellular transport via RFC (reduced folate carrier type) and be subject to more polyglutamation compared to methotrexate. The enhanced polyglutamylation ability of pralatrexate is associated with increased tumor cell death and ultimately improved anticancer activity. Pralatrexate is considered a promising drug for patients with recurrent and treatment-resistant PTCL with a good survival advantage. At the same time, it is an antifolate agent with a significant advantage over methotrexate as it does not cause myelosuppression.While there are manageable side effects such as thrombocytopenia, neutropenia, and mucositis, it is critical to explore new approaches, targeted agents, novel cellular therapies, and immunotherapies to determine optimal pretreatment in the rare but heterogeneous disease PTCL, and future studies and experienced haematologists are needed.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
晚意完成签到 ,获得积分10
2秒前
优雅的怀莲完成签到,获得积分10
2秒前
科研通AI2S应助Leo采纳,获得10
4秒前
绿色催化完成签到,获得积分10
4秒前
5秒前
朴实初夏完成签到 ,获得积分10
6秒前
万事屋完成签到 ,获得积分10
6秒前
HXJT完成签到,获得积分10
7秒前
bingo完成签到,获得积分10
7秒前
JACK完成签到,获得积分10
7秒前
深山何处钟声鸣完成签到 ,获得积分10
7秒前
隐形曼青应助Viva采纳,获得10
10秒前
Zhai完成签到 ,获得积分10
10秒前
bkagyin应助东方立轩采纳,获得10
11秒前
gengfu完成签到,获得积分10
11秒前
张一楠发布了新的文献求助10
11秒前
王纪钧发布了新的文献求助10
12秒前
华仔应助陶醉太阳采纳,获得10
14秒前
无奈的萍完成签到,获得积分10
16秒前
良辰应助Viva采纳,获得10
17秒前
zhaoyang完成签到 ,获得积分10
18秒前
华仔应助jilongwang采纳,获得10
19秒前
东方立轩完成签到,获得积分10
20秒前
CodeCraft应助曾经电源采纳,获得10
24秒前
24秒前
Julia发布了新的文献求助10
30秒前
王纪钧完成签到,获得积分10
31秒前
孟伟完成签到,获得积分10
37秒前
尤瑟夫完成签到 ,获得积分10
37秒前
37秒前
大方博涛完成签到,获得积分10
38秒前
123完成签到 ,获得积分10
38秒前
lifeup完成签到 ,获得积分10
39秒前
katrina完成签到 ,获得积分10
39秒前
Skywalker完成签到,获得积分10
39秒前
ccccc应助三十三采纳,获得20
41秒前
QY发布了新的文献求助10
43秒前
俊逸的篮球完成签到,获得积分10
43秒前
橡皮鱼完成签到,获得积分10
43秒前
赖雅绿完成签到,获得积分10
43秒前
高分求助中
Evolution 10000
ISSN 2159-8274 EISSN 2159-8290 1000
Becoming: An Introduction to Jung's Concept of Individuation 600
Ore genesis in the Zambian Copperbelt with particular reference to the northern sector of the Chambishi basin 500
A new species of Coccus (Homoptera: Coccoidea) from Malawi 500
A new species of Velataspis (Hemiptera Coccoidea Diaspididae) from tea in Assam 500
PraxisRatgeber: Mantiden: Faszinierende Lauerjäger 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3162539
求助须知:如何正确求助?哪些是违规求助? 2813402
关于积分的说明 7900247
捐赠科研通 2472973
什么是DOI,文献DOI怎么找? 1316615
科研通“疑难数据库(出版商)”最低求助积分说明 631375
版权声明 602175